| # | Title | Journal | Year | Citations |
|---|
| 1 | Fibroblast growth factors, their receptors and signaling. | Endocrine-Related Cancer | 2000 | 1,118 |
| 2 | BRAF mutation in thyroid cancer | Endocrine-Related Cancer | 2005 | 1,114 |
| 3 | Diabetes and cancer | Endocrine-Related Cancer | 2009 | 857 |
| 4 | Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients | Endocrine-Related Cancer | 2012 | 738 |
| 5 | The role of let-7 in cell differentiation and cancer | Endocrine-Related Cancer | 2010 | 567 |
| 6 | The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. | Endocrine-Related Cancer | 2001 | 558 |
| 7 | Mechanisms of tamoxifen resistance | Endocrine-Related Cancer | 2004 | 523 |
| 8 | Highly prevalent TERT promoter mutations in aggressive thyroid cancers | Endocrine-Related Cancer | 2013 | 500 |
| 9 | MicroRNA deregulation in human thyroid papillary carcinomas | Endocrine-Related Cancer | 2006 | 463 |
| 10 | Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition | Endocrine-Related Cancer | 2005 | 435 |
| 11 | Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression | Endocrine-Related Cancer | 2007 | 431 |
| 12 | Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors | Endocrine-Related Cancer | 2010 | 409 |
| 13 | Resveratrol and cancer: focus on in vivo evidence | Endocrine-Related Cancer | 2014 | 409 |
| 14 | mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. | Endocrine-Related Cancer | 2001 | 388 |
| 15 | MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle | Endocrine-Related Cancer | 2007 | 383 |
| 16 | Current and emerging biomarkers in breast cancer: prognosis and prediction | Endocrine-Related Cancer | 2010 | 380 |
| 17 | Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters | Endocrine-Related Cancer | 2010 | 374 |
| 18 | Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution | Endocrine-Related Cancer | 2014 | 370 |
| 19 | Discovery of a novel Raf kinase inhibitor. | Endocrine-Related Cancer | 2001 | 367 |
| 20 | Loss of ERβ expression as a common step in estrogen-dependent tumor progression | Endocrine-Related Cancer | 2004 | 367 |
| 21 | Molecular links between obesity and breast cancer | Endocrine-Related Cancer | 2006 | 366 |
| 22 | Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization | Endocrine-Related Cancer | 2005 | 360 |
| 23 | Management of patients with adrenal cancer: recommendations of an international consensus conference | Endocrine-Related Cancer | 2005 | 354 |
| 24 | Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer | Endocrine-Related Cancer | 2008 | 351 |
| 25 | Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies | Endocrine-Related Cancer | 2009 | 348 |
| 26 | Tumor-induced osteomalacia | Endocrine-Related Cancer | 2011 | 339 |
| 27 | Alternatively spliced androgen receptor variants | Endocrine-Related Cancer | 2011 | 337 |
| 28 | Epidermal growth factor receptor inhibition strategies in oncology | Endocrine-Related Cancer | 2004 | 327 |
| 29 | The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane | Endocrine-Related Cancer | 2006 | 324 |
| 30 | Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours | Endocrine-Related Cancer | 2008 | 324 |
| 31 | Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors | Endocrine-Related Cancer | 2008 | 320 |
| 32 | Receptor tyrosine kinase signalling as a target for cancer intervention strategies. | Endocrine-Related Cancer | 2001 | 319 |
| 33 | Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms | Endocrine-Related Cancer | 2015 | 316 |
| 34 | Histological and biological evolution of human premalignant breast disease. | Endocrine-Related Cancer | 2001 | 308 |
| 35 | c-Myc in breast cancer. | Endocrine-Related Cancer | 2000 | 304 |
| 36 | TERT promoter mutations in thyroid cancer | Endocrine-Related Cancer | 2016 | 301 |
| 37 | p53 and breast cancer, an update | Endocrine-Related Cancer | 2006 | 300 |
| 38 | Malignant pheochromocytoma: current status and initiatives for future progress | Endocrine-Related Cancer | 2004 | 299 |
| 39 | Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas | Endocrine-Related Cancer | 2011 | 299 |
| 40 | The role of fibroblast growth factors and their receptors in prostate cancer | Endocrine-Related Cancer | 2004 | 295 |
| 41 | The epidermal growth factor receptor as a target for cancer therapy. | Endocrine-Related Cancer | 2001 | 285 |
| 42 | Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. | Endocrine-Related Cancer | 2003 | 279 |
| 43 | The diagnosis and management of malignant phaeochromocytoma and paraganglioma | Endocrine-Related Cancer | 2007 | 279 |
| 44 | Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms | Endocrine-Related Cancer | 2011 | 275 |
| 45 | Are G3 ENETS neuroendocrine neoplasms heterogeneous? | Endocrine-Related Cancer | 2013 | 275 |
| 46 | EGF mutant receptor vIII as a molecular target in cancer therapy. | Endocrine-Related Cancer | 2001 | 274 |
| 47 | Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. | Endocrine-Related Cancer | 2003 | 274 |
| 48 | Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer | Endocrine-Related Cancer | 2013 | 272 |
| 49 | Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells | Endocrine-Related Cancer | 2004 | 271 |
| 50 | Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. | Endocrine-Related Cancer | 2001 | 270 |
